September 11, 2026
ELV’s CFO flagged better Q3 trends at Wells Fargo’s conference, and the stock jumped as UnitedHealth slid.
Managed care investors have spent the better part of two years waiting for one thing: a real-time signal that medical cost inflation inside the quarter is actually bending. On Thursday morning at the Wells Fargo 21st Annual Healthcare Conference, Elevance Health CFO Marc Kaye delivered it.
Pilots Use One. Smart Traders Should Too.
A pilot never takes off without running a checklist. Not because they don’t know how to fly – because they know that the moment something feels routine is the moment a step gets skipped.
Options trading punishes skipped steps faster than almost anything else. So, I put the 7 that matter most on one page.
It’s called the Smart Trade Options Checklist. Normally $29.97. Free today.
Run it before any options trade. Takes about 30 seconds. You’ll catch the bad ones before they cost you.
Why This Stock Now
Elevance stock surged nearly 6% in midday trading after the company filed a Form 8-K reaffirming its full-year 2026 adjusted EPS guidance of at least $27.00 per diluted share and signaled that third-quarter adjusted EPS is tracking ahead of the outlook it provided following second-quarter results. That combination, a live intra-quarter update and a guidance hold, is not routine disclosure. It is the closest thing to a pre-announcement the sector produces, and the market treated it accordingly.
The Business
Elevance operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits engine collects premiums from commercial, Medicare, and Medicaid members; CarelonRx and Carelon Services handle pharmacy and integrated care management. The pitch for 2026 has always been that those diversified legs would cushion the company through the managed-care cost cycle. This week’s update suggests the cushion is working ahead of schedule.
Management has said 2026 should be the trough year for Medicaid margins, with improvement expected in 2027 as rates better match costs; CarelonRx and Carelon Services are contributing through integrated medical and pharmacy management, AI tools, and clinical platform investments; and the company expects to return to at least 12% adjusted EPS growth in 2027 from the 2026 baseline, supported by multiple businesses rather than one segment alone.
The #1 Commodity Trade of 2026
Gold bugs are going to hate this. The #1 commodity trade of 2026 isn’t gold, silver, oil, or any rare earth metal. It’s something far more valuable – something The New York Times says “powers the world’s tech.”
And America controls over 80% of the world’s supply. When Trump restricts exports, Morgan Stanley estimates it could trigger a $10 trillion boom. And you have the rare opportunity to get in on the ground floor.
Why Wall Street Is Paying Attention
The intra-quarter update cited favorable benefit expense performance as a key driver and gave investors a meaningful positive data point well ahead of the company’s next scheduled earnings release. Earnings are expected on October 21. Getting confirmation in September that the third quarter is running hot narrows the guesswork considerably.
The contrast with UnitedHealth makes the ELV move more compelling, not less. In a separate Wells Fargo conference appearance, UnitedHealth’s CFO John Rex said the TPG-WellMed deal was a growth partnership rather than a capital raise, and the market treated the UNH selloff as company-specific. When the sector’s largest name drops about 3% and a peer rises nearly 6% on the same conference circuit, relative strength is speaking loudly.
What’s Driving the Opportunity
Elevance raised its 2026 adjusted EPS guidance to at least $27.00 and raised operating cash flow guidance to at least $6.0 billion after second-quarter results beat expectations in July. Thursday’s update from Kaye extends that beat into the current quarter. The stock had been consolidating in the low-to-mid $390s heading into the conference.
5 Nasdaq Stocks Under $5 That Aren’t What You Think
Most stocks under $5 come with a reputation. These don’t.
Each company on this list is tied to major trends like AI, cybersecurity, and next-gen infrastructure.
They may not have the spotlight yet, but they are building real businesses in real markets. That combination is not always easy to find at this price level.
Management has also reiterated that its 2026 operating cash flow guidance is at least $6.0 billion and pointed to continued favorable benefit expense performance in the third quarter. For investors who have waited for proof that medical cost management is working, that language, delivered mid-quarter, is the evidence they needed.
What Could Go Wrong
Elevance is not without risk. The stock has experienced volatility even around recent rallies, and the company faces challenges with narrowing margins and Medicaid pressures even as it targets improved profitability. Medicaid rate mismatches across states remain a structural drag that management itself called a 2026 trough, meaning any slippage in 2027 rate negotiations could delay the recovery. Analyst price targets vary widely, and consensus targets imply upside that is meaningful but not unlimited, so the market is not pricing in a runaway re-rating. That also means there is not much room for disappointment.
The Bottom Line
An intra-quarter cost improvement signal from a managed-care CFO is a rare and specific catalyst. It does not guarantee a clean October earnings report, but it substantially raises the probability. Elevance entered this week with questions about whether its medical cost actions were working. Marc Kaye answered them Thursday, and the stock moved nearly 6% in response while UnitedHealth slid about 3% on separate news tied to a TPG partnership involving WellMed clinics in Florida. That divergence tells you where institutional attention is going. If the late-October report confirms what September implied, today’s buyers will have been early rather than late.
